Earlier this March, Alosenta had the pleasure of attending the UK–Japan–Korea Bio-AI Open Innovation Forum in London, hosted at the Royal Society.
Representing Alosenta were our Co-Founder & CFO/COO, Inna Zhuranskaya, and Commercial Lead, Judy Kingswolf-Yamakawa, joining a highly engaged group of researchers, investors, and pharmaceutical innovators across the UK, Japan, and Korea.
The forum focused on building a unified “Bio-AI” ecosystem; connecting life sciences, digital technologies, and healthcare to accelerate therapeutic discovery and improve patient outcomes.
Indepth conversations across the two days around:
- Translating AI-driven discovery into clinical applications
- Structuring effective industry–academia–government collaboration
- Aligning international R&D ecosystems and funding frameworks
- Accelerating therapeutic development through open innovation
It was a valuable opportunity to strengthen relationships across the UK, Japan, and Korea, and to continue building towards a more connected global ecosystem for next-generation healthcare.